Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...

Atherosclerosis, a disease characterized by the accumulation of lipids and inflammatory cells in the arterial wall, is a ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. (Operator Instructions) Today's conference is being recorded. Thank you. I ...

In October 2024, Novartis announced that based on its review of 48-week data from the Phase 3 MANIFEST-2 study, longer follow-up time is needed to determine the regulatory path for pelabresib in ...

The merged entity will continue to develop Alumis’ two so-called TYK2 inhibitors, one of which is being developed for plaque ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

The other reflexes were lively, in favor of the left side. The Expanded Disability Score (EDDS) was 1.5. Cerebral MRI showed typical multiple sclerosis plaques in the right parietal region, a second ...

Oppenheimer initiated coverage on Alumis Inc (NASDAQ:ALMS) with an Outperform rating and a price target of $32.00. The firm's analysts highlighted the biopharmaceutical company's focus on developing ...

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS MASITINIB PLATFORMParis, January 29, 2025, 7pm CETAB Science SA (Euronext - FR0010557264 - AB) ...